Trisomy 21 is a recurrent secondary aberration in childhood acute lymphoblastic leukemia with TEL/AML1 gene fusion

Genes Chromosomes Cancer. 1999 Mar;24(3):272-7.

Abstract

TEL/AML1 gene fusion is the most frequent genetic lesion in pediatric acute lymphoblastic leukemia (ALL). It occurs as a consequence of the cryptic chromosomal translocation t(12;21)(p13;q22). In a cohort of 50 RT-PCR-positive TEL/AML1 patients, karyotype examination by GTG banding and fluorescence in situ hybridization (FISH) allowed us to identify chromosome anomalies in addition to the already existing t(12;21). Secondary aberrations were found in 29 out of 41 patients (71%) at initial diagnosis and in all 9 patients with relapse. Structural rearrangements affected chromosome arms 2p, 2q, 5q, 9p, 12p (n = 2), 6q, 11p (n = 3), and 21q (n = 4). An extra chromosome 21 was found to be the most frequent anomaly. It was detected in 6 out of 41 patients at initial diagnosis (15%) and in 7 out of the 9 patients at relapse. No karyotype with trisomy 21 exceeded 47 chromosomes. Gain of chromosome 21 was the sole anomaly in GTG-banding analysis in 2/41 patients at initial diagnosis and in 4/9 at relapse. Notably, chromosome painting analysis performed in 11 out of the 13 patients with an extra chromosome 21 revealed duplication of the normal chromosome 21 in 8, and duplication of der(21)t(12;21) in 3 patients. Furthermore, gain of der(21)t(12;21) chromosome was confined exclusively to the relapse patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Chromosome Aberrations / genetics*
  • Core Binding Factor Alpha 2 Subunit
  • Down Syndrome / genetics*
  • Humans
  • In Situ Hybridization, Fluorescence
  • Karyotyping
  • Neoplasm Proteins / genetics*
  • Oncogene Proteins, Fusion*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Recurrence
  • Translocation, Genetic / genetics*

Substances

  • Core Binding Factor Alpha 2 Subunit
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • TEL-AML1 fusion protein